{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    6,
    7,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "Amendment 2",
        "affectedSection": "Synopsis; 9.2.2; 11.3.1.2; 11.3.2.2",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified US-specific definition of clinical remission and its application to the analysis population."
      },
      {
        "id": "impact_2",
        "amendmentId": "Amendment 2",
        "affectedSection": "Synopsis; 2.1.3; 9.2.1; 9.1.2; 9.2.2.3; 11.3.3; Table 1",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added Bristol Stool Form Scale as a new exploratory efficacy evaluation and endpoint."
      },
      {
        "id": "impact_3",
        "amendmentId": "Amendment 2",
        "affectedSection": "Table 1; Table 2; Table 3; Attachment 4",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified TB testing requirements specifically for study centers in Ukraine."
      },
      {
        "id": "impact_4",
        "amendmentId": "Amendment 2",
        "affectedSection": "Synopsis; 2.1.2.2; 9.2.2.2.2; 11.2.2",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Reordered secondary objectives and updated analysis population for corticosteroid-free remission."
      },
      {
        "id": "impact_5",
        "amendmentId": "Amendment 2",
        "affectedSection": "Section 5 - Treatment Allocation and Blinding",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified unblinding procedures for futility analysis and database locks."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "Amendment 2",
        "reasonText": "To address health authority requests for additional data collection and provide further clarifications.",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "Amendment 2",
        "reasonText": "To address investigator feedback regarding protocol implementation.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "Amendment 2",
        "reasonText": "Collection of stool consistency data using the Bristol Stool Form Scale added at health authority request.",
        "category": "Regulatory",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "Amendment 2",
        "reasonText": "Tuberculin skin test availability issues in Ukraine required alternative testing guidance.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_5",
        "amendmentId": "Amendment 2",
        "reasonText": "Update to reflect availability of highly effective antiviral therapy for Hepatitis C clearance.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "Amendment 2",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.2.2",
        "afterText": "The following US-specific definition of clinical remission will be used in the United States: an absolute stool number ≤3, a rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0 or 1.",
        "summary": "Defined US-specific clinical remission criteria for regulatory submission."
      },
      {
        "id": "change_2",
        "amendmentId": "Amendment 2",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "2.1.3",
        "afterText": "To evaluate the data based on the Bristol Stool Form Scale score in the induction study.",
        "summary": "Added exploratory objective for Bristol Stool Form Scale."
      },
      {
        "id": "change_3",
        "amendmentId": "Amendment 2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1",
        "beforeText": "Hemoglobin 8.0 g/dL",
        "afterText": "Hemoglobin 8.0 g/dL (SI: ≥80.0 g/L)",
        "summary": "Added International System of Units (SI) equivalents to laboratory parameters."
      },
      {
        "id": "change_4",
        "amendmentId": "Amendment 2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.2",
        "beforeText": "Are seropositive for antibodies to hepatitis C virus (HCV)",
        "afterText": "Are seropositive for antibodies to hepatitis C virus (HCV) without a history of successful treatment, defined as being negative for HCV RNA at least 24 weeks after completing antiviral treatment.",
        "summary": "Updated HCV exclusion criteria to allow for clinically cured subjects."
      },
      {
        "id": "change_5",
        "amendmentId": "Amendment 2",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1",
        "beforeText": "budesonide",
        "afterText": "budesonide or beclomethasone dipropionate",
        "summary": "Included beclomethasone dipropionate as an allowed corticosteroid formulation."
      },
      {
        "id": "change_6",
        "amendmentId": "Amendment 2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "11.3.2.3",
        "afterText": "A fixed-sequence testing procedure will be employed for the United States to strongly control the overall Type 1 error rate at the 0.05 level across the primary and all 4 major secondary endpoints.",
        "summary": "Implemented fixed-sequence testing for US regulatory requirements."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 5,
      "changeCount": 6
    }
  }
}